CsA is a major contributing factor in the development of posttransplant renal dysfunction in marrow transplant patients. The wide interpatient variability in CsA concentration (Fig 3), the narrow therapeutic index of CsA, and the significant correlation between CsA concentration and renal dysfunction suggest that monitoring of trough CsA concentrations may be helpful in minimizing unnecessary renal toxicity, at least in marrow transplant recipients. Further studies are needed to determine whether CsA concentration correlates with prevention of graft-v-host disease. Co-administration of potentially nephrotoxic drugs during CsA therapy should be avoided or minimized if possible.
|Original language||English (US)|
|Number of pages||6|
|Issue number||4 SUPPL. 1|
|State||Published - Dec 1 1985|
ASJC Scopus subject areas